BusinessActinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant OrganizationsBy Nasdaq OMXFeb 28, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Commencement of Rights Offering Subscription PeriodBy Nasdaq OMXFeb 22, 2018, 12:31 PM UTC
BusinessActinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant OrganizationsBy Nasdaq OMXFeb 20, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of RecordBy Nasdaq OMXFeb 12, 2018, 12:30 PM UTC
BusinessActinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on MyeloablationBy Nasdaq OMXFeb 8, 2018, 1:01 PM UTC
BusinessActinium Pharmaceuticals Reminds Investors of Record Date for Rights OfferingBy Nasdaq OMXFeb 7, 2018, 2:01 PM UTC
BusinessActinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML PatientsBy Nasdaq OMXFeb 6, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals to Present at the BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 5, 2018, 9:15 PM UTC
